Biocysan Patent Granted in the USA by USPTO

Bio3 Research S.r.l., Milan – Italy, has been granted by the USPTO a patent which claims the use of oral L-cysteine (Biocysan®) in patients with impaired renal functions who are exposed to severe anemia and to oxidative stress.

Milano (I-Newswire) October 2, 2012 - Bio3 Research S.r.l., Milan – Italy, has been granted by the United States Patent and Trademark Office (USPTO) the US patent No. 101/583,334 which claims the oral use of L-cysteine (Biocysan®), in patients with impaired renal functions who are exposed to severe anemia and to oxidative stress.

The US patent grant strengthens Bio3 Research patent portfolio with Biocysan®.
In addition to the USA, Biocysan® patents have now been granted to Bio3 Research in Canada, Mexico (NAFTA) and also in Europe. Biocysan® patent is pending (very final phase) in Japan.

Bio3 Research has started the commercialisation in several countries, via local distributors, of Biocysan® (oral L-cysteine – pulse release formulation), a dietary supplement, based on the captioned granted patents, to counteract oxidative stress in chronic kidney disease patients and to alleviate anemia.
Bio3 Research has also started Biocysan® worldwide sale via e-commerce.

Biocysan® acts as support treatment in Chronic Kidney Disease patients to prevent severe anemia, due to Glutathione (GSH) low levels and to reduce oxidative stress, via re-establishing Glutathione levels (GSH). GSH is instrumental for the synthesis of stable erythrocytes which ultimately are the key transporters of oxigen in the body cells. No other oral Pulse Release formulations based on L-Cysteine are available in the market.



About Bio3 Research S.r.l.
Bio3 Research s.r.l. develops new proprietary compounds with therapeutic potential in the cardiovascular and connective tissue regeneration fields. The company is developing the protein HMGB1 and its fragments for use in connective-tissue regeneration (healing of wounds, burns and bedsores; cartilage repair; bone matrix regeneration, rheumatoid arthritis, systemic lupus erythematosus). Bio3 Research also develops compounds (HMGB1 fragments) to inhibit systemic HMGB1 levels, for use in cardiovascular disorders (restenosis, arterial stenosis, treatment of atherosclerotic plaque progression). As a separate line of business, Bio3 Research has also developed and markets in several countries Biocysan® www.biocysan.com (oral L-cysteine – pulse release formulation), a dietary supplement to counteract oxidative stress in chronic kidney disease patients and to alleviate anemia. Bio3 Research has also started Biocysan® worldwide sale via e-commerce (http://www.biocysan.com/buynow.html).
Additional information on Bio3 Research can be obtained from the official website www.bio3research.com.